Discover the detailed record of transactions filed by Blume-Jensen Peter. Director active across 1 company, notably Acrivon Therapeutics, Inc.. Cumulatively, 26 reports have been published. Split: 1 buy · 3 sells. Total volume traded: €100k. Activity tracked since 14 November 2022. The latest transaction was filed on 25 August 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Blume-Jensen Peter
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Blume-Jensen Peter is a declarant linked to Acrivon Therapeutics, Inc. on XNAS, where the listed role is President and CEO. He has 23 filings in total, and within the sampled recent filings the purchases total 70538 EUR and the sales total 0 EUR, over a period from 2022-11-16 to 2026-05-26, with Retenue fiscale as the most frequent transaction nature.